Multiple Sclerosis and Related Disorders Template
Write in a clean editor, then format for Multiple Sclerosis and Related Disorders in one click — DocuGuru applies the official Elsevier template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Multiple Sclerosis and Related Disorders format
Multiple Sclerosis and Related Disorders is a peer-reviewed journal published by Elsevier, covering Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Systemic Sclerosis and Related Diseases.
| Publisher | Elsevier |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Multiple Sclerosis and Related Disorders, 12(3), pp. 45–58.
Formats any DOI in Multiple Sclerosis and Related Disorders style. No sign-up. |
| Publishes research in | Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Systemic Sclerosis and Related Diseases Polyomavirus and related diseases Amyotrophic Lateral Sclerosis Research |
| ISSN | 2211-0348 |
| Citation impact (2-yr) | 2.26 |
| h-index | 87 |
| i10-index | 2,422 |
| Total citations | 80,212 |
| Article processing charge | $3,020 |
| Top institutions publishing here | Queen Mary University of London |
| Journal website | www.sciencedirect.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Multiple Sclerosis and Related Disorders per year
Citation impact of Multiple Sclerosis and Related Disorders by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Multiple Sclerosis and Related Disorders
The management of multiple sclerosis is becoming increasingly complex with the emergence of new and more effective disease-modifying therapies (DMT). We propose a new treatment paradigm that individualises treatment based on a choice between two interchangeable therapeutic strategies of maintenance-escalation or induction therapy. We propose treating- to-target of no evident disease activity (NEDA) as defined…
BACKGROUND: No drug has been found to have any impact on progressive multiple sclerosis (MS). Biotin is a vitamin acting as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acids synthesis. Among others, biotin activates acetylCoA carboxylase, a potentially rate-limiting enzyme in myelin synthesis. OBJECTIVES: The aim of this pilot…